AndhraNews.net
Home » Business News » 2013 » October » October 8, 2013

Southeasterners Believe Brain Cancer Diagnosis Is Death Sentence as Revealed in New Survey


October 8, 2013 - South Miami, FL

A new survey commissioned by the Miami Neuroscience Center (MNC) reveals that a majority of Southeasterners in the U.S. believe there is no hope for survival when brain tumors are diagnosed. The MNC survey, conducted by Toluna Global Research, randomly surveyed a cross section of men and women over the age of 25 in Florida, Georgia, and Alabama.

In responding to "The Brain tumor I.Q. Test" Survey, only 24% of the general population and 23% of Hispanics reported they believed brain tumors could be treated despite the fact that nearly 95% of general respondents and 89% of Hispanic respondents said they or someone they knew had a brain, head, or neck tumor removed or treated. When thinking of brain tumors, 54% of general respondents and 53% of Hispanics said that what came to mind was fear.

Miami Neuroscience Center Medical Director Dr. Azik Wolf, one of the world's leading authorities on radiosurgery and the Gamma Knife, a technologically innovative, non-invasive treatment for brain, head, and neck cancers, said the survey results should be a wake up call to the medical community. "It is very disturbing to realize that despite the extraordinary advances in brain cancer treatment, so many people are unaware that many brain cancers can be treated and are survivable." Dr. Wolf believes doctors need to use this information to better communicate with brain cancer patients. "From the moment a patient is diagnosed, I believe every doctor has a responsibility to help their patients understand treatment options and explain their particular situation in understandable terms. For most, there is reason for optimism," explained Dr. Wolf.

For a majority of survey respondents, getting a referral from their doctor when considering brain cancer surgery was not a priority. 84% of the general population and some 70% of Hispanics responding said it was the surgical team's experience that mattered most followed by surgical equipment and technologies. Interestingly, Hispanic respondents ranked bilingual medical staff as their least important consideration.

The Miami Neuroscience Center is a state-of-the-art facility housing one of the nation's premier Gamma Knife® surgery programs. Not an actual knife, the Gamma Knife is considered the gold standard in radiosurgery. It is a sophisticated non-invasive system that delivers high-dose radiation to the target treatment site without damaging surrounding tissue. Its extreme precision makes it the most effective system for controlling tumors in the brain, head and neck.

Internationally recognized for its groundbreaking work in radiosurgery, the Miami Neuroscience Center utilizes the Gamma Knife Perfexion, the only neurosurgical tool specifically designed for noninvasive brain, neck, and cervical spine radiosurgery. Led by Dr. Wolf, the Miami Neuroscience Center team has been working together for more than 20 years, achieving national and international acclaim for its development of groundbreaking advancements in radiosurgery. The Miami Neuroscience Center is located at Larkin Community Hospital.

About Larkin Community Hospital:
Larkin Community Hospital (LCH) is an Acute Care Medical, Surgical and Psychiatric Teaching Hospital fully accredited by the Joint Commission on Accreditation of Healthcare Organizations. Located in South Miami, Florida, LCH is one of 12 designated Statutory Teaching Hospitals in Florida and the largest teaching hospital for Osteopathic physicians in the United States, offering training in 29 different specialties including a Registered Nurse Associate Degree program. The hospital is home to the Miami Neuroscience Center, one of the nation's leading Gamma Knife Surgery programs and the only one of its kind in southeast Florida. For more information about Larkin Community Hospital, visit www.larkinhospital.com.

Media
Contact
Carmen Coya
404-408-2103
Email: clcoya@effectivemedia.co

MarketWire

Comment on this story

Share